When treating refractory kidney cancer, clinicians prioritize regimens offering the most durable initial response. They argue against “saving” effective drugs for later, as disease progression is traumatic for patients and many never successfully receive subsequent lines of therapy. The goal is long-term disease control now, not preserving theoretical future options.

With pirtobrutinib, time to next treatment often exceeds progression-free survival. This discrepancy exists because disease progression is frequently slow and asymptomatic, meaning clinicians do not need to switch therapies immediately upon seeing radiographic changes, allowing for longer treatment duration.

Traditional endpoints like progression-free survival (PFS) incentivize continuous treatment. The NCI group proposes "treatment-free survival," a novel metric that quantifies time spent *off* therapy. This endpoint better captures the patient experience and rewards treatments that provide durable responses after a finite course.

A key emerging characteristic of belzutifan-based therapies is their ability to produce a long-lasting duration of response. This creates a notable "tail of the curve" in survival plots, suggesting belzutifan adds significant durability to combination regimens.

Dr. Carbone argues that traditional metrics like median survival or response rate are less relevant for immunotherapies. The true measure of success is the percentage of patients alive at five or six years—the "tail of the curve"—as this indicates a durable, potentially curative, response.

The LITESPARK 011 trial showed the Lenvatinib/Belzutifan combination doubled the duration of response compared to Cabozantinib. This durability, with some patients in remission for over three years, is considered a more significant clinical advance than the modest increase in overall response rate, representing a key differentiator for the regimen.

While depth of response strongly predicts survival for an individual patient, the FDA analysis concludes it cannot yet be used as a surrogate endpoint to replace overall survival in pivotal clinical trials. It serves as a measure of drug activity, similar to response rate, but is not sufficient for drug approval on its own.

The GLORA-IV trial is designed with a dual endpoint, evaluating both patient response rate and overall survival. This structure creates an alternative pathway for regulatory approval based on response rates, which can be assessed faster than survival, strategically de-risking the lengthy and expensive trial process.

Immunotherapies can be effective even without causing significant tumor shrinkage. Immunocore's drug KimTrack had a low 5-7% objective response rate (ORR) but demonstrated a massive overall survival (OS) benefit, challenging the reliance on traditional chemotherapy metrics for evaluating modern cancer treatments.